Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mov Disord ; 39(6): 1065-1070, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38610104

ABSTRACT

BACKGROUND: The GPNMB single-nucleotide polymorphism rs199347 and GBA1 variants both associate with Lewy body disorder (LBD) risk. GPNMB encodes glycoprotein nonmetastatic melanoma protein B (GPNMB), a biomarker for GBA1-associated Gaucher's disease. OBJECTIVE: The aim of this study was to determine whether GPNMB levels (1) differ in LBD with and without GBA1 variants and (2) associate with rs199347 genotype. METHODS: We quantified GPNMB levels in plasma and cerebrospinal fluid (CSF) from 124 individuals with LBD with one GBA1 variant (121 plasma, 14 CSF), 631 individuals with LBD without GBA1 variants (626 plasma, 41 CSF), 9 neurologically normal individuals with one GBA1 variant (plasma), and 2 individuals with two GBA1 variants (plasma). We tested for associations between GPNMB levels and rs199347 or GBA1 status. RESULTS: GPNMB levels associate with rs199347 genotype in plasma (P = 0.022) and CSF (P = 0.007), but not with GBA1 status. CONCLUSIONS: rs199347 is a protein quantitative trait locus for GPNMB. GPNMB levels are unaltered in individuals carrying one GBA1 variant. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


Subject(s)
Biomarkers , Glucosylceramidase , Lewy Body Disease , Membrane Glycoproteins , Polymorphism, Single Nucleotide , Humans , Female , Glucosylceramidase/genetics , Male , Lewy Body Disease/genetics , Lewy Body Disease/cerebrospinal fluid , Lewy Body Disease/blood , Membrane Glycoproteins/genetics , Membrane Glycoproteins/cerebrospinal fluid , Aged , Middle Aged , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Aged, 80 and over , Genotype , Heterozygote , Gaucher Disease/genetics , Gaucher Disease/blood , Gaucher Disease/cerebrospinal fluid
2.
PLoS One ; 10(3): e0120194, 2015.
Article in English | MEDLINE | ID: mdl-25775479

ABSTRACT

Gaucher disease, a recessive inherited metabolic disorder caused by defects in the gene encoding glucosylceramidase (GlcCerase), can be divided into three subtypes according to the appearance of symptoms associated with central nervous system involvement. We now identify a protein, glycoprotein non-metastatic B (GPNMB), that acts as an authentic marker of brain pathology in neurological forms of Gaucher disease. Using three independent techniques, including quantitative global proteomic analysis of cerebrospinal fluid (CSF) in samples from Gaucher disease patients that display neurological symptoms, we demonstrate a correlation between the severity of symptoms and GPNMB levels. Moreover, GPNMB levels in the CSF correlate with disease severity in a mouse model of Gaucher disease. GPNMB was also elevated in brain samples from patients with type 2 and 3 Gaucher disease. Our data suggest that GPNMB can be used as a marker to quantify neuropathology in Gaucher disease patients and as a marker of treatment efficacy once suitable treatments towards the neurological symptoms of Gaucher disease become available.


Subject(s)
Gaucher Disease/cerebrospinal fluid , Membrane Glycoproteins/cerebrospinal fluid , Adolescent , Amino Acid Sequence , Animals , Biomarkers/cerebrospinal fluid , Biomarkers/metabolism , Brain/metabolism , Case-Control Studies , Child , Female , Gaucher Disease/metabolism , Gaucher Disease/pathology , Humans , Male , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , Molecular Sequence Data
3.
J Inherit Metab Dis ; 31(6): 745-52, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18850301

ABSTRACT

We report three siblings with Gaucher disease type III, born between 1992 and 2004. During this period, new developments resulted in different potential therapies, changing clinical practice. The two eldest siblings received enzyme replacement therapy (ERT) from the age of 24 and 5 months respectively, later followed by an increase in dosage. ERT was combined with substrate reduction therapy (SRT) from the ages of 12 and 8 years, respectively. In the youngest sibling the combination of high-dose ERT and SRT was given from the age of 5 months. The two eldest siblings showed significant neurological impairment from the age of 1.5 years, starting with a convergent strabismus and partial oculomotor apraxia, followed by cognitive decline and an abnormal EEG and BAER. In contrast, the neurological development in the youngest sibling is almost completely normal. At the age of 3 years, cognitive development, EEG and BAER are all normal. Disturbed saccadic eye movements, which were already present at the start of therapy, remained stable. In addition to the clinical efficacy, we report on the biochemical response to therapy. Based on our results, the combination of high-dose ERT and SRT should be considered as a possible therapeutic approach for GD III, especially if started at a young age. Further follow-up studies are necessary to explore the long-term therapeutic effects.


Subject(s)
Enzyme Therapy , Gaucher Disease/diagnosis , Gaucher Disease/drug therapy , Chemokine CCL3/blood , Chemokine CCL3/cerebrospinal fluid , Chemokine CCL4/blood , Chemokine CCL4/cerebrospinal fluid , Child , Child, Preschool , Family Health , Female , Gaucher Disease/blood , Gaucher Disease/cerebrospinal fluid , Hexosaminidases/blood , Hexosaminidases/cerebrospinal fluid , Homozygote , Humans , Mutation , Time Factors , Treatment Outcome
4.
J Inherit Metab Dis ; 25(1): 47-55, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11999980

ABSTRACT

The lipid composition or the liver, spleen, brain, cerebellum and cerebrospinal fluid of a Gaucher disease type II patient who died at the age of 5 months was examined. The glycolipid analysis demonstrated a marked increase of total amounts not only in the peripheral tissues but also in the brain cerebellum and cerebrospinal fluid, with a prevalence of glucosylceramide. A reduction in gangliosides was observed in all the analysed tissues with a relative increase of GD3 in the nervous tissue. The fatty acid composition of glucosylceramide showed a prevalence of stearic acid in the central nervous system, while in the peripheral tissues palmitic acid was prevalent. This result suggests a different origin of the glucosylceramide stored in different tissues. The generalized reduction of gangliosides and their modified distribution together with the central nervous system GD3 increment represent a new observation. These data could be useful in the effort to clarify the pathophysiological mechanism of brain damage in neuronopathic Gaucher disease.


Subject(s)
Gaucher Disease , Glycolipids/analysis , Brain/pathology , Brain Chemistry , Cerebellum/chemistry , Cerebellum/pathology , Female , G(M1) Ganglioside/analysis , G(M1) Ganglioside/cerebrospinal fluid , Gangliosides/analysis , Gangliosides/cerebrospinal fluid , Gaucher Disease/cerebrospinal fluid , Gaucher Disease/pathology , Gaucher Disease/physiopathology , Glucosylceramides/analysis , Glucosylceramides/cerebrospinal fluid , Glycolipids/cerebrospinal fluid , Humans , Infant , Lactosylceramides/analysis , Lactosylceramides/cerebrospinal fluid , Liver/chemistry , Liver/pathology , Spleen/chemistry , Spleen/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...